At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- MRI pelvis or CT imaging under clinical management for Pr Ca (other), Whole body bone scan imaging (other), PET-CT imaging (other)
- How long the study runs
- Study runs about 206 months (dates as stated)
- About the drug or intervention
- MRI pelvis or CT imaging under clinical management for Pr Ca — other: Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images. · Whole body bone scan imaging — other: bone scan of the whole body (under clinical diagnosis). · PET-CT imaging — other: Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is looking at a type of scan called FCH PET-CT in men with prostate cancer who also have an inherited change (mutation) in a DNA repair gene, such as BRCA1, BRCA2, ATM or CHEK2. The study wants to see how well this scan shows prostate cancer. It is run by the Institute of Cancer Research in the United Kingdom.
Who can take part
- Men over 18 with prostate cancer
- A confirmed inherited (germline) mutation in one of these genes: BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2 or ATM
- Needing a staging scan, either at new diagnosis, after previous surgery or radiotherapy (more than 6 months ago) with rising PSA and no current hormone treatment or chemotherapy, or on active surveillance with a PSA doubling time of 6 months or less
Who may not be able to
- Another cancer in the last 5 years (apart from certain skin cancers)
- Prostate cancer that has already spread
- Any cancer treatment in the last 6 months
- Taking part in another drug trial
- Taking steroids
- A history of inflammatory or infective diseases, such as sarcoidosis, tuberculosis or inflammatory bowel disease
- Anything that makes an MRI unsafe, such as a pacemaker, aneurysm clips or severe claustrophobia
What taking part involves
- • Having an FCH PET-CT scan
- • Not stated — ask the trial team about any other tests or procedures
Time commitment: Not stated — ask the trial team how many visits are needed, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- Male
- Number of participants
- 50
- Started
- 2015-10-15
- Last checked
- 2025-12
Plain English Summary
What is this study?
- • Testing a new treatment for prostate cancer
- • Clinical study - 50 participants
- • The aim of the study is to determine if PET-CT imaging (using contrast recommended in clinical guidelines) is superior to combined bone scan and MRI/CT of the abdomen \& pelvis in detecting the increased incidence of metastasis (nodal/distant outside the pelvis) in men with prostatic carcinoma with mutations in any of the following germline DNA repair genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2, ATM
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with prostate cancer
- • Male only
Where?
- • London - Cancer Genetics Unit, Royal Marsden Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The aim of the study is to determine if PET-CT imaging (using contrast recommended in clinical guidelines) is superior to combined bone scan and MRI/CT of the abdomen \& pelvis in detecting the increased incidence of metastasis (nodal/distant outside the pelvis) in men with prostatic carcinoma with mutations in any of the following germline DNA repair genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2, ATM.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: Male only
Biomarkers mentioned
What the study is looking for
- ✓Confirmed pathogenic germline mutation in any of the following genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2,...
- ✓Over the age of 18
- ✓Diagnosed with prostate cancer and at a time when staging imaging is clinically indicated; either:
- ✓At a new diagnosis
- ✓Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago)...
Who cannot take part
- ✗Diagnosis of other cancer (excluding basal cell cancer/squamous cell cancer of the skin) within five years of...
- ✗Known that has spread prostate cancer, both local and distant
- ✗Patients who have received any oncological treatment within the last six months
- ✗Patients on any investigational drug treatment
- ✗Patients on steroids
See the full criteria
Where Is This Study? (1 UK site)
Cancer Genetics Unit, Royal Marsden Hospital
London SM2 5PT, United Kingdom
How to Get in Touch
Rosalind A Eeles, FRCP FRCR
Sponsor contactCONTACT
Elizabeth K Bancroft, PhD
Sponsor contactCONTACT